VT
vTv Therapeutics Inc.
VTVT · NASDAQ
$31.30 -0.48% (-$0.15)
1M -6.17%
Market Cap $82.3M
P/E Ratio -
Div. Yield -
ROE 6.27%
Bulios Fair Price
$37.3
19.2% upside
Current Price
$31.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VTVT is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
86 /100
Cheap P/B 1.05x
P/S 2.23x
EV/FFO N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Op. margin 25.11%
Gross margin 100.00%
FCF margin 45.50%
Quality
5 /100
Poor ROA 5.43%
ROIC 11.48%
Asset turnover 0.42x
Debt
69 /100
Low Int. coverage -1,066.17x
Debt/Equity 0.00x
Current ratio 12.48x
Stability
31 /100
Unstable Profitable years 0
Beta 0.29x
EPS volatility 37.95%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VTVT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Paul J. Sekhri
Employees
26
Headquarters
High Point
Upcoming events
05 NOV
Earnings
Upcoming earnings report